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Background and Aims: The combination of Sofosbuvir (SOF), apolymerase inhibitor, plus Simeprevir 
(SMV), a protease inhibitor(PI), with or without ribavirin (RBV), has shown a good efficacy and safety 
profile in compensated cirrhotic patients infected with thehepatitis C virus (HCV) genotype (GT) 1 or 4. 
To date, there is no available data regarding the efficacy of this combination in real-life cirrhotic patients 
in Spain. The aim of this multicentric study was to assess the Spanish clinical experience using 
SOF/SMV (±RBV) in a large cohort of real-life compensated cirrhotic patients. 
 
Methods: Retrospective analysis of data from GT1 and GT4 infected cirrhotic patients treated with this 
oral antiviral combination. 
 
Results: Six-hundred and 22 cirrhotic patients were included. Cirrhosis was defined according to clinical, 
histological, ultrasonographic or elastographic criteria. The majority of patients were male (62%) and the 
median age was 59 years (23–80). Patients were infected with GT1a (20%), 1b (67%) or 4 (10%). The 
median transient elastographic measurement was 21.8 KPa (P2516.6; P7533.3); the MELD score was 
8(5–26) and the majority of patients(73.5%) were Child-Pugh A at baseline. Up to 58.5% of patients had 
previously failed to antiviral therapies; importantly 17% of them had already received a PI-based 
regimen. Baseline median ALT was 69(5–513) and viral load (HCV-RNA) was 6.06 log10IU/mL (1.28–
8.29). The majority of patients (78%) were treated for 12 weeks and 62% of the cohort received RBV. 
Fourteen patients are still on treatment; 8patients had to prematurely discontinue therapy (1 due to an 
allergic reaction, 1 committed suicide, 1 had hepatocellular carcinoma progression, 2 patients presented 
liver decompensation and in 3cases was unknown). At the end of treatment (EOT), all patients had 
undetectable serum HCV-RNA. The rates of sustained virological response (SVR) 4 and 12 weeks after 
therapy were 95.5% (485/505)and 88.5% (415/469), respectively. SVR rate was similar among patients, 
regardless of the use or not of RBV. There were 54 (8.7%) reported virological failures. Safety profile 
will be reported.   
 
Conclusions: The combination of SOF/SMV (with or without RBV) isvery effective in cirrhotic patients 
infected with GT1 and 4 in Spain.The high prevalence of G1b infection may explain the higher 
efficacycompared with other real-life cohorts. 
 
